Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.83 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.71 |
| ▸ | HTR1A | P08908 | 6/20 | 0.69 |
| ▸ | HTR2A | P28223 | 4/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.69 |
| ▸ | HTR1D | P28221 | 2/20 | 0.69 |
| ▸ | HTR1B | P28222 | 2/20 | 0.69 |
| ▸ | HTR2C | P28335 | 2/20 | 0.69 |
| ▸ | HTR7 | P34969 | 2/20 | 0.69 |
| ▸ | HTR6 | P50406 | 2/20 | 0.69 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.69 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.69 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 2/20 | 0.68 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9329211 | 0.96 | CYP2D6 (0.81) | CYP2D6SLC6A4HTR1AHTR2ACYP1A2 | |
| SCHEMBL5360884 | 0.94 | CYP2D6 (0.79) | CYP2D6SLC6A4HTR1AHTR2ACYP1A2 | |
| SCHEMBL5350306 | 0.94 | CYP2D6 (0.79) | CYP2D6SLC6A4HTR1AHTR2ACYP1A2 | |
| SCHEMBL5368511 | 0.94 | CYP2D6 (0.79) | CYP2D6SLC6A4HTR1AHTR2ACYP1A2 | |
| SCHEMBL5363947 | 0.94 | CYP2D6 (0.79) | CYP2D6SLC6A4HTR1AHTR2ACYP1A2 | |
| SCHEMBL5362738 | 0.94 | CYP2D6 (0.79) | CYP2D6SLC6A4HTR1AHTR2ACYP1A2 | |
| SCHEMBL676574 | 0.91 | CYP2D6 (1.00) | CYP2D6SLC6A4HTR1AHTR2ACYP1A2 | |
| SCHEMBL29375720 | 0.91 | CYP2D6 (1.00) | CYP2D6SLC6A4HTR1AHTR2ACYP1A2 | |
| SCHEMBL18929855 | 0.87 | SLC6A4 (0.72) | CYP2D6SLC6A4HTR1AHTR2ACYP1A2 | |
| SCHEMBL8558403 | 0.85 | SLC6A4 (0.71) | CYP2D6SLC6A4HTR1AHTR2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110511174-B | Indolylalkyl piperazine compound and application thereof | 复旦大学 | 2023-03-28 | — | — | CN | disclosed |
| EP-3027607-B1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2020-08-26 | — | — | EP | disclosed |
| CN-110511174-A | A kind of indolyl piperazine compounds and its application | UNIV FUDAN | 2019-11-29 | — | — | CN | disclosed |
| US-9598401-B2 | Substituted heteroaryl compounds and methods of use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-03-21 | — | — | US | disclosed |
| EP-3027607-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2016-06-08 | — | — | EP | disclosed |
| US-20160083370-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-03-24 | — | — | US | disclosed |
| WO-2015169180-A1 | SUBSTITUTED PIPERAZINE COMPOUNDS AND METHODS AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-11-12 | — | — | WO | disclosed |
| WO-2015014256-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-02-05 | — | — | WO | disclosed |
| EP-0747379-B1 | Derivatives of indole, indazole and benzisoxazole for the treatment of schizophrenia | ADIR (FR) | 1999-08-11 | — | — | EP | disclosed |
| US-5703070-A | PSYCHOLOGICAL DISORDERS | ADIR ET COMPAGNIE (FR) | 1997-12-30 | — | — | US | disclosed |
| EP-0747379-A1 | Derivatives of indole, indazole and benzisoxazole for the treatment of schizophrenia | ADIR ET COMPAGNIE (FR) | 1996-12-11 | — | — | EP | disclosed |
| EP-0714896-A1 | INDOL DERIVATIVES USEFUL FOR THE TREATMENT OF MIGRAINE, COMPOSITION AND UTILIZATION | VITA-INVEST, S.A. (ES) | 1996-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083370-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HTR3B, HTR3A, HTR2C | CYP2D6 180/4885SLC6A4 19/4885HTR1A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.